**Summary:** This study investigates how HIV-1 Tat protein enhances NF-κB activation through interaction with TRAF6, a key upstream signaling molecule in the canonical NF-κB pathway. The research reveals that Tat directly activates NF-κB by interacting with TRAF6, leading to TRAF6 oligomerization, auto-ubiquitination, and the synthesis of K63-linked polyubiquitin chains, which further activate the NF-κB pathway and enhance HIV-1 transcription. These findings demonstrate that TRAF6 is essential for Tat-mediated NF-κB activation, which is independent of P-TEFb and distinct from Tat's role in enhancing viral elongation. The study also shows that this mechanism is conserved among HIV-1, HIV-2, and SIV isolates, highlighting a new mechanism by which HIV-1 subverts host transcriptional pathways to enhance its own transcription. Additionally, the study identifies key residues in the cysteine-rich domain of Tat that are critical for TRAF6-mediated NF-κB activation, and shows that Tat enhances NF-κB activation through a direct interaction with TRAF6, which is independent of UBE2O. The results suggest that TRAF6 is a novel host factor for Tat in HIV-1 transcription and for latency reactivation through the regulation of NF-κB activity. The study also shows that TRAF6-mediated NF-κB activation by Tat is independent of P-TEFb binding, and that the cysteine-rich region of Tat is involved in the formation of the binding surface for TRAF6. The study further demonstrates that TRAF6-mediated NF-κB activation by Tat is conserved among primate lentiviruses, indicating that this mechanism has been functionally conserved during viral evolution. The findings provide new insights into the molecular mechanisms by which HIV-1 and other primate lentiviruses manipulate host signaling pathways to enhance their own transcription and replication.**Summary:** This study investigates how HIV-1 Tat protein enhances NF-κB activation through interaction with TRAF6, a key upstream signaling molecule in the canonical NF-κB pathway. The research reveals that Tat directly activates NF-κB by interacting with TRAF6, leading to TRAF6 oligomerization, auto-ubiquitination, and the synthesis of K63-linked polyubiquitin chains, which further activate the NF-κB pathway and enhance HIV-1 transcription. These findings demonstrate that TRAF6 is essential for Tat-mediated NF-κB activation, which is independent of P-TEFb and distinct from Tat's role in enhancing viral elongation. The study also shows that this mechanism is conserved among HIV-1, HIV-2, and SIV isolates, highlighting a new mechanism by which HIV-1 subverts host transcriptional pathways to enhance its own transcription. Additionally, the study identifies key residues in the cysteine-rich domain of Tat that are critical for TRAF6-mediated NF-κB activation, and shows that Tat enhances NF-κB activation through a direct interaction with TRAF6, which is independent of UBE2O. The results suggest that TRAF6 is a novel host factor for Tat in HIV-1 transcription and for latency reactivation through the regulation of NF-κB activity. The study also shows that TRAF6-mediated NF-κB activation by Tat is independent of P-TEFb binding, and that the cysteine-rich region of Tat is involved in the formation of the binding surface for TRAF6. The study further demonstrates that TRAF6-mediated NF-κB activation by Tat is conserved among primate lentiviruses, indicating that this mechanism has been functionally conserved during viral evolution. The findings provide new insights into the molecular mechanisms by which HIV-1 and other primate lentiviruses manipulate host signaling pathways to enhance their own transcription and replication.